Antheia Rakes In $17 Million in New Funding

MENLO PARK &&num;8212&semi; Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, announced &dollar;17 million in new funding via a government project agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), alongside matching support from new strategic investors&period; The combined funding will support onshoring the production of critical pharmaceutical ingredients to the U&period;S&period; and accelerating the company&&num;8217&semi;s commercialization strategy&period; The funding includes a non-dilutive two-year project agreement up to &dollar;11 million through the BioMaP Consortium and additional investment from In-Q-Tel, Inc&period; (IQT), Echo Investment Capital (Echo), and several existing investors, including Viking Global Investors&period;&NewLine;&&num;8220&semi;Biotechnology has a critical role to play in U&period;S&period; national and economic security,&&num;8221&semi; said Dr&period; Christina Smolke, Antheia CEO and co-founder&period; &&num;8220&semi;With the support of both the public and private sectors, we can leverage this technology to bolster essential medicine production in the U&period;S&period;, with an agile, scalable biomanufacturing approach that leapfrogs existing pharmaceutical manufacturing practices&period;&&num;8221&semi;&NewLine;The BioMaP-Consortium is a multiple-purpose acquisition vehicle supporting the Biomedical Advanced Research and Development Authority (BARDA) and is composed of pharmaceutical, medical, academic, and scientific organizations&period; This project has been funded in whole or in part with federal funds from the U&period;S&period; Department of Health and Human Services&semi; Administration for Strategic Preparedness and Response (ASPR)&semi; Office of Industrial Base Manufacturing and Supply Chain (IBMSC), under OT number &num;75A50123D00003&period;&NewLine;The BioMaP-Consortium aims to meet the U&period;S&period; public health preparedness and response requirements by expanding the industrial and manufacturing base for medical countermeasures&period; As part of the BioMaP-Consortium award, Antheia will demonstrate the domestic production of three critical pharmaceutical ingredients at population scale using advanced biomanufacturing processes&period;&NewLine;In addition to the BioMaP-Consortium project agreement, Antheia brought in matching support from new strategic investors – including IQT and Echo – that represent the intersection of innovation, national security, and domestic manufacturing&period; IQT connects cutting edge innovation from the private sector to the U&period;S&period; government and its allies to advance national security in the 21st century&period; Echo is a multi-strategy investment firm that connects overlooked domestic resources and infrastructure with world-class founders, ideas, and capital to generate exceptional financial and social returns&period;&NewLine;&&num;8220&semi;The U&period;S&period; is a leader in biomanufacturing, synthetic biology, and computational biology, but there is more we must do to scale these advanced technologies to solve global problems like essential medicine shortages,&&num;8221&semi; said Eugene Chiu, Senior Partner, IQT&period; &&num;8220&semi;We are excited to support Antheia in advancing the U&period;S&period; bioeconomy and building resilient pharmaceutical supply chains&period;&&num;8221&semi;&NewLine;&&num;8220&semi;Antheia&&num;8217&semi;s disruptive innovation is dramatically changing the outlook for security and resiliency of our biopharmaceutical supply chains,&&num;8221&semi; said Christian Kanady, Founding Partner &amp&semi; CEO, Echo&period; &&num;8220&semi;We are proud to partner in advancing Antheia&&num;8217&semi;s groundbreaking technologies and importantly renewing the domestic bioeconomy in the process&period;&&num;8221&semi;&NewLine;

Editor